Cd155

CD155, originally named "cellular receptor for poliovirus", is a leading member of a subfamily of immunoglobulin-like adhesion receptors. CD155 is upregulated during tumor progression and promotes the proliferative and migratory capabilities of tumor cells through multiple pathways. CD155 (PVR) is dramatically overexpressed in several human malignancies, whereas its expression is low or absent in most healthy tissues. Consistent with PVR biology, its overexpression promotes tumor cell invasion, migration, and proliferation and is associated with poor prognosis and increased tumor progression.

Furthermore, CD155 transmits immune signals by interacting with the inhibitory checkpoint receptor TIGIT, thereby inhibiting T and NK cell function. CD155 plays a role in the establishment of junctional connections between the individual cells of the intestinal epithelium and thus its integrity.

CD155 is involved in the humoral immune response of the gastrointestinal immune system.

Oncology: Several preclinical studies have demonstrated that monotherapeutic TIGIT blockade or TIGIT blockade in combination with other immune checkpoint inhibitors are suitable for the treatment of advanced solid malignant tumors.

1. Georgiev HG et al (2018) Coming of Age: CD96 Emerges as Modulator of Immune Responses. Front. Immunol 9: 1072.

2. Kučan Brlić P et al (2019) Targeting CD155 (PVR)(CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16:40-52.

3. Liu L et al (2021) CD155/TIGIT, a novel immune checkpoint in human cancers (Review). Oncology Reports 45: 835-845.

4. Maier MK et al (2007) The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens. Eur J Immunol37: 2214-2225